Company Overview - Shanghai United Imaging Healthcare Co., Ltd. specializes in providing high-performance medical imaging equipment, radiation therapy products, life science instruments, and digital healthcare solutions globally [1] - The main products include MRI systems, CT systems, XR systems, molecular imaging systems, medical linear accelerators, animal MRI, animal PET/CT, United Imaging Cloud platform, cloud film, cloud PACS, and digital healthcare solutions [1] Financial Performance - For Q1 2025, the company reported revenue of 2.478 billion yuan, a year-on-year increase of 5.42% [2] - The net profit for the same period was 370 million yuan, reflecting a year-on-year growth of 1.87% [2] - The gross profit margin stood at 49.94% [2] Market Position - As of July 2, the company's stock closed at 126.15 yuan, down 1.48%, with a rolling PE ratio of 81.95 times [1] - The total market capitalization reached 103.968 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing the company at the 102nd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 21,435, up by 3,165 from the previous count [1] - The average market value of shares held per shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Intellectual Property - The company has applied for a total of 11,502 intellectual property rights, of which 5,882 have been granted [1] - During the reporting period, the company filed 1,079 new intellectual property applications and received 707 grants, including 766 invention patent applications and 465 granted invention patents [1]

Group 1 - The core viewpoint of the articles highlights the resurgence of headquarters projects in Guanggu, attracting significant foreign investment from global leading companies and Fortune 500 firms [1][2][3] - In 2025, the Wuhan Investment Promotion Conference resulted in the signing of 10 major projects in Guanggu, with a total investment amounting to 16.74 billion yuan [1] - Guanggu has signed over 60 projects worth more than 100 million yuan this year, indicating a consistent trend of investment activity [1] Group 2 - The "second headquarters" phenomenon in Guanggu began in 2017, with over 80 leading internet companies and numerous major enterprises establishing their second headquarters in the region by 2020 [2] - The focus of Guanggu's investment strategy is not merely on scale but on aligning with regional strategies and supporting industrial upgrades, thereby enhancing the local industrial ecosystem [2] - Guanggu has attracted over 1,300 foreign enterprises, including nearly 100 Fortune 500 companies, with more than 120 foreign enterprises registered last year, accounting for nearly 30% of new foreign investment enterprises in the city [3] Group 3 - The efficient business environment in Guanggu has been a key factor in attracting foreign investment, with companies like Amber Group citing quick establishment processes as a significant advantage [6] - Guanggu has optimized its foreign investment policies, introducing new incentives for development, research, and green initiatives, which have led to over a hundred foreign enterprises benefiting from these policies [7] - Recent initiatives include the establishment of overseas offices by local companies and the signing of agreements with international firms, enhancing Guanggu's global connectivity [7][8]

Market Overview - As of July 1, 2025, the three major A-share indices showed mixed performance, with the Shanghai Composite Index rising by 0.39% to 3457.75 points, the Shenzhen Component Index increasing by 0.11% to 10476.29 points, and the ChiNext Index declining by 0.24% to 2147.92 points. The total trading volume of the two markets reached 1.47 trillion yuan [1]. Industry Performance - The glass and fiberglass sector performed notably well, surging by 5.11%, followed by professional chains and chemical pharmaceuticals, which rose by 4.04% and 2.96%, respectively [1]. - The overall market saw 562 non-currency ETFs increase, representing 48% of the total [1]. ETF Performance - The Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index rose by 2.99%, with various ETFs tracking this index, such as the Science and Technology Medicine ETF and the Science and Technology Biomedicine ETF, showing increases between 3.02% and 3.18% [1]. - The China Securities Hong Kong-Shenzhen Innovation Drug Industry Index increased by 1.13%, with the Innovation Drug ETFs from Fortune and Guotai rising by 5.88% and 3.90%, respectively [1]. Specific ETF Details - The Innovation Drug ETF from Fortune (159748.SZ) has a latest share size of 548 million, closely tracking the China Securities Hong Kong-Shenzhen Innovation Drug Industry Index, which includes major companies like WuXi AppTec and Innovent Biologics [2]. - The latest PE-TTM for the China Securities Hong Kong-Shenzhen Innovation Drug Industry Index is 40.00, which is lower than 82.73% of the time over the past three years [3]. - The Hong Kong Stock Connect Innovation Drug ETF (159570.SZ) has a share size of 5.129 billion and tracks the National Securities Hong Kong Stock Connect Innovation Drug Index, which includes companies like Innovent Biologics and WuXi Biologics [3]. - The Science and Technology Medicine ETF (588860.SH) has a share size of 1.42 billion and tracks the Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index, featuring companies such as BeiGene and Hualan Biological Engineering [4]. Declining ETFs - The overall market saw 514 non-currency ETFs decline, accounting for 44% of the total, with the China Securities Financial Technology Theme Index and the China Securities All-Index Software Index experiencing the largest drops of 2.84% and 1.70%, respectively [4]. - The Financial Technology ETF (516860.SH) has a share size of 608 million and tracks the China Securities Financial Technology Theme Index, which includes companies like Eastmoney Information and Tonghuashun [6].

Group 1 - The medical device sector is experiencing strong performance, with the medical device ETF (159797) rising by 1.08% and attracting net inflows for the second consecutive day [1][3] - The majority of the constituent stocks of the medical device ETF saw gains, with notable increases such as Hotgen Biotech rising over 11%, and Xiangyu Medical and Xinmai Medical both increasing over 8% [3] - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, which includes enhancing the use of medical insurance data for drug research and improving the dynamic adjustment mechanism for the basic medical insurance drug list [3] Group 2 - The release of the RuiPath pathology model by Ruijin Hospital marks a significant advancement in domestic medical AI, transitioning from technical breakthroughs to ecosystem sharing [4] - The measures approved by the National Medical Products Administration aim to optimize the lifecycle regulation to support the innovation of high-end medical devices, including improving special approval processes and enhancing communication mechanisms [5] - The external skeleton robot industry is viewed positively due to recent technological breakthroughs and product innovations, with applications in both medical and industrial sectors expected to grow rapidly [6][7] Group 3 - The medical device ETF (159797) encompasses a wide range of medical equipment and diagnostics, with the top ten weighted stocks accounting for nearly 47% of the fund [7][8] - The top holdings in the medical device ETF include Mindray Medical (14.65%), United Imaging Healthcare (9.44%), and Aimeike (3.95%) among others [8]

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF, which has seen significant trading volume and asset growth, indicating investor interest in the sector [3] - As of June 30, the Kexin Pharmaceutical ETF has achieved a net value increase of 27.37% over the past year, with a maximum monthly return of 23.29% since inception [3] - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [3][5] Group 2 - Recent measures from the National Healthcare Security Administration and the National Health Commission support the use of medical insurance data for innovative drug development, enhancing collaboration among healthcare, insurance, and pharmaceutical sectors [5] - East China Securities emphasizes the importance of innovative drugs as a core investment theme, suggesting investors focus on companies with differentiated product offerings and strong potential for growth [6] - The global pharmaceutical investment landscape is recovering, positively impacting the CXO and upstream life sciences sectors, leading to improved order and financial performance [6]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.93% as of July 1, 2025, with notable gains from stocks such as Rongchang Biopharmaceutical (688331) up 7.21% and Shanghai Yizhong (688091) up 3.61% [1] - Starting July 1, 2025, a new policy mandates that all drug sales must include a verification code for medical insurance reimbursement, with full traceability of drug codes required by January 1, 2026, which is expected to enhance drug circulation regulation and impact the entire pharmaceutical industry chain [1] - The current bull market in innovative drugs is driven by the improvement of China's pharmaceutical innovation capabilities, with a trend towards international collaboration in new drug development expected to enhance profitability and market potential for Chinese pharmaceutical companies [2] Group 2 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [3] - The Sci-Tech Biopharmaceutical ETF closely tracks the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in various biopharmaceutical sectors [2]

上海联影医疗科技股份有限公司关于公司董事离任 及选举第二届董事会职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2025 年 6 月 30 日召开股东会审议通过《关于取消监事会及修订 <公司章程> 的议 案》，根据《公司章程》，公司设职工代表董事 1 名，由公司职工通过职工代 表大会民主选举产生。公司于 2025 年 6 月 30 日召开职工代表大会并做出决 议，选举 TAO CAI 先生为公司第二届董事会职工董事。 证券代码：688271 证券简称：联影医疗 公告编号：2025-028 二、选举第二届董事会职工董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》（以下简称"《规范运作》"） 等相关法律法规，公司已于 2025 年 6 月 30 日召开股东会审议通过《关于取消监 事会及修订 <公司章程> 的议案》。 根据《公司章程》，公司设职工代 ...

证券代码：688271 证券简称：联影医疗 公告编号：2025-027 海分公司"）就核查对象在自查期间买卖公司股票及其衍生品种的情况进行了查 询确认，并由中登上海公司出具了《信息披露义务人持股及股份变更查询证明》 和《股东股份变更明细清单》。 关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票及其衍生品种情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、核查对象买卖公司股票的情况说明 上海联影医疗科技股份有限公司 上海联影医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日召开了第二届董事会第二十一次会议、第二届监事会第十三次会议审议通过了 《关于公司<2025 年限制性股票激励计划(草案)>及其摘要的议案》等相关议案， 并于 2025 年 6 月 14 日在上海证券交易所网站（www.sse.com.cn）上披露了相关 公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）等有关 法律、法规和规范性文件以及《上海联影医疗科技股份有限公司章程》的规定， ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight increase recently, but has experienced declines over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 1.02% to 13,488.91 points with a trading volume of 17.167 billion yuan [1]. - Over the past month, the index has decreased by 0.36%, by 4.69% over the last three months, and by 2.45% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1]. - The index was established on December 31, 2004, with a base value of 1,000 points [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: Mindray Medical (9.73%), United Imaging (8.3%), Aier Eye Hospital (7.64%), Aimeike (3.47%), Huatai Medical (3.3%), New Industry (2.93%), Yuyue Medical (2.81%), Lepu Medical (2.38%), Meinian Onehealth (2.11%), and Shandong Pharmaceutical Glass (1.93%) [1]. Group 4: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.23%) and the Shanghai Stock Exchange (39.77%) [1]. - All holdings in the index are categorized under the pharmaceutical and healthcare sector, accounting for 100% [1]. Group 5: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the healthcare index include various Southern and Tianhong funds, as well as ETFs from multiple financial institutions [2].

关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票及其衍生品种情况的自查报告 证券代码：688271 证券简称：联影医疗 公告编号：2025-027 上海联影医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海联影医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日召开了第二届董事会第二十一次会议、第二届监事会第十三次会议审议通过了 《关于公司<2025 年限制性股票激励计划(草案)>及其摘要的议案》等相关议案， 并于 2025 年 6 月 14 日在上海证券交易所网站（www.sse.com.cn）上披露了相关 公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）等有关 法律、法规和规范性文件以及《上海联影医疗科技股份有限公司章程》的规定， 公司对 2025 年限制性股票激励计划（以下简称"本次激励计划"）采取了充分 必要的保密措施，同时对本次激励计划的内幕信息知情人进行了必要登记。根据 《管理办法》《上海证券交易所科创板股票上市规则》《科创板上市 ...